Tendinopathy - Pipeline Insight, 2022

Tendinopathy - Pipeline Insight, 2022

DelveInsight’s, Tendinopathy - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tendinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Tendinopathy Understanding

Tendinopathy: Overview

Tendinopathies are very common in general population and a huge number of tendon-related procedures take place annually worldwide, with significant socio-economic repercussions. Numerous treatment options are commonly used for tendon disorders. Tendon disorders are a class of pathology that includes traumatic injuries as well as chronic diseases, such as tendinopathy. They represent some of the most frequent orthopedic diagnosis, accounting for over 30% of all musculoskeletal consultations. Over 30 million human tendon-related procedures take place annually worldwide with significant socio-economic repercussions in terms of lost working hours and economic expenditure.

Numerous treatment options are proposed in the treatment of patients affected by tendinopathies. Usually, they can be grouped in pharmacological therapies, physical therapies, and therapeutic exercise.

""Tendinopathy - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tendinopathy pipeline landscape is provided which includes the disease overview and Tendinopathy treatment guidelines. The assessment part of the report embraces, in depth Tendinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tendinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Tendinopathy. The therapies under development are focused on novel approaches to treat/improve Tendinopathy.

Tendinopathy Emerging Drugs

dHACM: MiMedx

dHACM is a micronized dehydrated Human Amnion Chorion Membrane developed by MiMedx for Tendinitis and is currently in the phase III stage of development. AmnioFix is processed using Purion, a unique patented method for placental-based allografts according to the American Association of Tissue Banks (AATB) standards. The product is derived from donated C-sections of live births in the US. The product faces active preservation of the extracellular matrix (ECM), regulatory proteins, and elimination of blood contaminants through a proprietary cleansing process. For an additional level of safety, the product is terminally sterilized.

Further product details are provided in the report……..

Tendinopathy: Therapeutic Assessment

This segment of the report provides insights about the Tendinopathy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Tendinopathy

There are approx. 5+ key companies which are developing the therapies Tendinopathy. The companies which have their Tendinopathy drug candidates in the most advanced stage, i.e phase III include MiMedx

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Tendinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tendinopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tendinopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tendinopathy drugs.

Tendinopathy Report Insights

• Tendinopathy Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tendinopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Tendinopathy drugs?
• How many Tendinopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tendinopathy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tendinopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tendinopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• MiMedx
• Hisamitsu Pharmaceuticals
• Seikagaku Corporation
• MetrioPharm

Key Products

• dHACM
• Diclofenac sodium transdermal patch
• SI-613
• MP1032


Please Note: It will take 7-10 business days to complete the report upon order confirmation.